SEC Comment Letter 0000000000-23-011820 to SOLENO THERAPEUTICS INC (SLNO) (CIK 0001484565) (SLNO)
SOLENO THERAPEUTICS INC (SLNO) (CIK 0001484565)
Date: Oct. 27, 2023 · CIK: 0001484565 · Accession: 0000000000-23-011820
AI Filing Summary & Sentiment
File numbers found in text: 333-275120
Letter
United States securities and exchange commission logo October 27, 2023 James Mackaness Chief Financial Officer Soleno Therapeutics, Inc. 203 Redwood Shores Pkwy, Suite 500 Redwood City, CA 94065 Re:Soleno Therapeutics, Inc. Registration Statement on Form S-3 Filed October 20, 2023 File no. 333-275120 Dear James Mackaness: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at 202-551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Jesse Schumaker, Esq.
Show Raw Text
United States securities and exchange commission logo
October 27, 2023
James Mackaness
Chief Financial Officer
Soleno Therapeutics, Inc.
203 Redwood Shores Pkwy, Suite 500
Redwood City, CA 94065
Re:Soleno Therapeutics, Inc.
Registration Statement on Form S-3
Filed October 20, 2023
File no. 333-275120
Dear James Mackaness:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at 202-551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Jesse Schumaker, Esq.